Preparation and structure of drug-carrying biodegradable microspheres designed for transarterial chemoembolization therapy

References

• Lencioni R, Petruzzi P, Crocetti L. Chemoembolization of hepatocellular carcinoma. Semin. Intervent. Radiol. 2013;30:3–11.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907–1917.10.1016/S0140-6736(03)14964-1
   PubMed Web of Science ®Google Scholar
• Kessel D, Ray C, editors. Transcatheter Embolization and Therapy. London: Springer; 2009.
   Google Scholar
• Bottsford-Miller JN, Coleman RL, Sood AK. Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. J. Clin. Oncol. 2012;30:4026–4034.10.1200/JCO.2012.41.9242
   PubMed Web of Science ®Google Scholar
• Wang B, Xu H, Gao ZQ, Ning HF, Sun YQ, Cao GW. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol. 2008;49:523–529.10.1080/02841850801958890
   PubMed Web of Science ®Google Scholar
• Welker MW, Trojan J. Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety. Cancer Manag. Res. 2013;5:337–347.
   PubMedGoogle Scholar
• Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov. 2006;5:835–844.10.1038/nrd2130
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008;359:378–390.10.1056/NEJMoa0708857
   PubMed Web of Science ®Google Scholar
• Rimassa L, Pressiani T, Boni C, Carnaghi C, Rota Caremoli E, Fagiuoli S, Foa P, Salvagni S, Cortesi E, Chiara Tronconi M, Personeni N, Bozzarelli S, Chiara Banzi M, Fanello S, Romano Lutman F, Giordano L, Santoro A. A phase II randomized dose escalation trial of sorafenib tosylate in patients with advanced hepatocellular carcinoma. Oncologist. 2013;18:379–380.10.1634/theoncologist.2012-0221
   PubMed Web of Science ®Google Scholar
• Cabrera R, Pannu DS, Caridi J, Firpi RJ, Soldevila-Pico C, Morelli G, Clark V, Suman A, George TJ Jr, Nelson DR. The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma. Aliment. Pharmacol. Ther. 2011;34:205–213.10.1111/apt.2011.34.issue-2
   PubMed Web of Science ®Google Scholar
• Bai W, Wang YJ, Zhao Y, Qi XS, Yin ZX, He CY, Li RJ, Wu KC, Xia JL, Fan DM, Han GH. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study. J. Dig. Dis. 2013;14:181–190.10.1111/cdd.2013.14.issue-4
   PubMed Web of Science ®Google Scholar
• Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, Takayama T, Yoon JH, Hori T, Kumada H, Hayashi N, Kaneko S, Tsubouchi H, Suh DJ, Furuse J, Okusaka T, Tanaka K, Matsui O, Wada M, Yamaguchi I, Ohya T, Meinhardt G, Okita K. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur. J. Cancer. 2011;47:2117–2127.10.1016/j.ejca.2011.05.007
   PubMed Web of Science ®Google Scholar
• Sansonno D, Lauletta G, Russi S, Conteduca V, Sansonno L, Dammacco F. Transarterial Chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-Related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. Oncologist. 2012;17:359–366.10.1634/theoncologist.2011-0313
   PubMed Web of Science ®Google Scholar
• Choi GH, Shim JH, Kim MJ, Ryu MH, Ryoo BY, Kang YK, Shin YM, Kim KM, Lim YS, Lee HC. Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses. Radiology. 2013;269:603–611.10.1148/radiol.13130150
   PubMed Web of Science ®Google Scholar
• Qu XD, Chen CS, Wang JH, Yan ZP, Chen JM, Gong GQ, Liu QX, Luo JJ, Liu LX, Liu R, Qian S. The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma. BMC Cancer. 2012;12:263.10.1186/1471-2407-12-263
   PubMed Web of Science ®Google Scholar
• Zhang L, Hu P, Chen X, Bie P. Transarterial chemoembolization (TACE) plus sorafenib tosylate versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis. PLoS ONE. 2014;9:e100305.10.1371/journal.pone.0100305
   PubMed Web of Science ®Google Scholar
• Hecq JD, Lewis AL, Vanbeckbergen D, Athanosopoulos A, Galanti L, Jamart J, Czuczman P, Chung T. Doxorubicin-loaded drug-eluting beads (DC Bead®) for use in transarterial chemoembolization: a stability assessment. J. Oncol. Pharm. Pract. 2013;19:65–74.10.1177/1078155212452765
   PubMedGoogle Scholar
• Lewis AL, Gonzalez MV, Lloyd AW, Hall B, Tang Y, Willis SL, Leppard SW, Wolfenden LC, Palmer RR, Stratford PW. dc bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J. Vasc. Interv. Radiol. 2006;17:335–342.10.1097/01.RVI.0000195323.46152.B3
   PubMed Web of Science ®Google Scholar
• Lewis AL. DC Bead: a major development in the toolbox for the interventional oncologist. Expert Rev Med Devices. 2009;6:389–400.10.1586/erd.09.20
   PubMed Web of Science ®Google Scholar
• Wang Y, van den Akker NM, Molin DG, Gagliardi M, van der Marel C, Lutz M, Knetsch ML, Koole LH. A nontoxic additive to introduce x-ray contrast into poly(lactic acid). Implications for transient medical implants such as bioresorbable coronary vascular scaffolds. Adv. Healthc. Mater. 2014;3:290–299.10.1002/adhm.v3.2
   PubMed Web of Science ®Google Scholar
• Rasband W. ImageJ; Image Processing and analysis in Java. Research Services Branch, National Institute of Mental Health, Bethesda, MD. Available from: http://rsb.info.nih.gov/ij/
   Google Scholar
• Spenlehauer G, Veillard M, Benoit JP. Formation and characterization of cisplatin loaded poly(D,L-lactide) microspheres for chemoembolization. J. Pharm. Sci. 1986;75:750–755.10.1002/(ISSN)1520-6017
   PubMed Web of Science ®Google Scholar
• Huo D, Deng S, Li L, Ji J. Studies on the poly(lactic-co-glycolic) acid microspheres of cisplatin for lung-targeting. Int. J. Pharm. 2005;289:63–67.10.1016/j.ijpharm.2004.10.017
   PubMed Web of Science ®Google Scholar
• Amol SP, Pramila T, Senthilkumar GP, Tamizh MT, Parag SM, Jagtap SB. UV spectrometric determination of sorafenib tosylate tosylate in bulk and pharmaceutical dosage form. Am. J. Pharmtech. Res. 2012;2:356–361.
   Google Scholar
• Golla ED, Ayres GH. Spectrophotometric determination of platinum with o-phenylenediamine. Talanta. 1973;20:199–210.10.1016/0039-9140(73)80267-X
   PubMed Web of Science ®Google Scholar
• Beril A, Güler Y, Filiz A, Emre D. The spectrophotometric determination of cisplatin in urine, using o-phenylenediamine as derivatizing agent. Anal. Lett. 2001;34:113–123.
   Web of Science ®Google Scholar
• Carpentier G, Martinelli M, Courty J, Cascone I. Angiogenesis Analyzer for ImageJ, 4th ImageJ User and Developer Conference Proceedings, Mondorf-les-Bains, Luxembourg; 2012. p. 198–201. ISBN: 2-919941-18-6. Available from: http://imagej.nih.gov/ij/macros/toolsets/Angiogenesis%20Analyzer.txt
   Google Scholar
• Sundquist WI, Ahmed KJ, Hollis LS, Lippard SJ. Solvolysis reactions of cis- and trans-diamminedichloroplatinum(II) in dimethyl sulfoxide. Structural characterization and DNA binding of trans-bis(ammine)chloro(DMSO)platinum(1+). Inorg. Chem. 1987;26:1524–1528.10.1021/ic00257a013
   Web of Science ®Google Scholar
• Li WI, Anderson KW, Mehta RC, Deluca PP. Prediction of solvent removal profile and effect on properties for peptide-loaded PLGA microspheres prepared by solvent extraction/ evaporation method. J. Controlled Release. 1995;37:199–214.10.1016/0168-3659(95)00076-3
   Web of Science ®Google Scholar
• Park TG, Yong Lee H, Sung Nam Y. A new preparation method for protein loaded poly(D,L-lactic-co-glycolic acid) microspheres and protein release mechanism study. J Controlled Release. 1998;55:181–191.10.1016/S0168-3659(98)00050-9
   PubMed Web of Science ®Google Scholar
• Nexavar: EPAR – Scientific Discussion. 04/03/2007. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Scientific_Discussion/human/000690/WC500027707.pdf
   Google Scholar
• Lee YS, Lowe JP, Gilby E, Perera S, Rigby SP. The initial release of cisplatin from poly(lactide-co-glycolide) microspheres. Int. J. Pharm. 2010;383:244–254.10.1016/j.ijpharm.2009.09.021
   PubMed Web of Science ®Google Scholar
• Machida Y, Onishi H, Kurita A, Hata H, Morikawa A, Machida Y. Pharmacokinetics of prolonged-release CPT-11-loaded microspheres in rats. J. Controlled Release. 2000;66:159–175.10.1016/S0168-3659(99)00267-9
   PubMed Web of Science ®Google Scholar
• Fredenberg S, Wahlgren M, Reslow M, Axelsson A. The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems – A review. Int. J. Pharm. 2011;415:34–52.10.1016/j.ijpharm.2011.05.049
   PubMed Web of Science ®Google Scholar
• Jalil R, Nixon JR. Biodegradable poly(lactic acid) and poly(lactide-co-glycolide) microcapsules: problems associated with preparative techniques and release properties. J. Microencapsul. 1990;7:297–325.10.3109/02652049009021842
   PubMed Web of Science ®Google Scholar
• Makino K, Ohshima H, Kondo T. Mechanism of hydrolytic degradation of poly(L-lactide) microcapsules: effects of pH, ionic strength and buffer concentration. J. Microencapsul. 1986;3:203–212.10.3109/02652048609031574
   PubMedGoogle Scholar
• Proikakis CS, Mamouzelos NJ, Tarantili PA, Andreopoulos AG. Stability of DL-poly(lactic acid) in aqueous solutions. J. Appl. Polym. Sci. 2003;87:795–804.10.1002/(ISSN)1097-4628
   Web of Science ®Google Scholar
• Fuertes MA, Castilla J, Alonso C, Pérez JM. Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr. Med. Chem. 2003;10:257–266.10.2174/0929867033368484
   PubMed Web of Science ®Google Scholar
• Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006;66:11851–11858.10.1158/0008-5472.CAN-06-1377
   PubMed Web of Science ®Google Scholar
• Vinchon-Petit S, Jarnet D, Michalak S, Lewis A, Benoit JP, Menei P. Local implantation of doxorubicin drug eluting beads in rat glioma. Int. J. Pharm. 2010;402:184–189.10.1016/j.ijpharm.2010.09.013
   PubMed Web of Science ®Google Scholar
• Senturk C, Cakir V, Yorukoglu K, Yilmaz O, Goktay AY. Looking for the ideal particle: an experimental embolization study. Cardiovasc. Intervent. Radiol. 2010;33:336–345.10.1007/s00270-009-9747-8
   PubMed Web of Science ®Google Scholar
• Forster RE, Tang Y, Bowyer C, Lloyd AW, Macfarlane W, Phillips GJ. Development of a combination drug-eluting bead. Anti-Cancer Drugs. 2012;23:355–369.10.1097/CAD.0b013e32835006d2
   PubMed Web of Science ®Google Scholar